Related Experiment Videos

Enzymatic diagnostic test for Muscle-Eye-Brain type congenital muscular dystrophy using commercially available

Wenli Zhang1, Jiri Vajsar, Pinjiang Cao

  • 1Department of Structural Biology and Biochemistry, The Hospital for Sick Children, 555 University Avenue, Ont. M5G 1X8, Toronto, Canada.

Clinical Biochemistry
|July 10, 2003
PubMed
Abstract

Insights

A diagnostic test for Muscle-Eye-Brain disease (MEB) was developed by measuring Protein O-Mannosyl beta-1,2-N-acetylglucosaminyltransferase 1 (POMGnT1) enzyme activity in muscle biopsies. MEB patients showed significantly decreased POMGnT1 activity.

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Congenital muscular dystrophies (CMDs) encompass a group of inherited muscle disorders.
  • Mutations affecting the dystroglycan complex can lead to CMDs with neurological and ocular manifestations.
  • Muscle-Eye-Brain disease (MEB) is an autosomal recessive CMD linked to mutations in the POMGnT1 gene.

Purpose of the Study:

  • To develop a diagnostic test for Muscle-Eye-Brain disease (MEB).
  • To investigate the utility of measuring Protein O-Mannosyl beta-1,2-N-acetylglucosaminyltransferase 1 (POMGnT1) enzyme activity for MEB diagnosis.

Main Methods:

  • Muscle biopsies were obtained from four MEB patients and control individuals.
  • POMGnT1 enzyme activity was quantified using commercially available reagents.

Main Results:

  • All four MEB patient muscle samples exhibited significantly reduced POMGnT1 enzyme activity compared to controls.
  • This decrease in activity suggests a functional deficiency in POMGnT1 in MEB patients.

Conclusions:

  • Assessing POMGnT1 activity in muscle biopsies offers a rapid and straightforward diagnostic method for MEB.
  • Given the heterogeneity of CMDs with brain malformations, POMGnT1 assays should be considered for screening MEB in affected patients.

Related Concept Videos